Impact of Porphyromonas gingivalis-odontogenic infection on the pathogenesis of non-alcoholic fatty liver disease

References

• Lazarus JV, Mark HE, Anstee QM, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19(1):1–12. doi:10.1038/s41575-021-00523-4.
   PubMed Web of Science ®Google Scholar
• Hernaez R, Peck-Radosavljevic M. MAFLD, HCC and the dilemma of (changing) terminology in liver diseases. Gut. 2023;72(1):9–11. doi:10.1136/gutjnl-2022-326992.
   PubMed Web of Science ®Google Scholar
• Kanneganti M, Singal AG. Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease. Gastro­enterology. 2022;162(6):1772–1774. doi:10.1053/j.gastro.2022.01.037.
   PubMedGoogle Scholar
• Foerster F, Gairing SJ, Muller L, et al. NAFLD-driven HCC: safety and efficacy of current and emerging treatment options. J Hepatol. 2022;76(2):446–457. doi:10.1016/j.jhep.2021.09.007.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672–2682. doi:10.1002/hep.30251.
   PubMed Web of Science ®Google Scholar
• Wong WK, Chan WK. Nonalcoholic fatty liver disease: a global perspective. Clin Ther. 2021;43(3):473–499. doi:10.1016/j.clinthera.2021.01.007.
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhou F, Wang W, et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology. 2020;71(5):1851–1864. doi:10.1002/hep.31150.
   PubMed Web of Science ®Google Scholar
• Gallage S, Avila JEB, Ramadori P, et al. A researcher’s guide to preclinical mouse NASH models. Nat Metab. 2022;4(12):1632–1649. doi:10.1038/s42255-022-00700-y.
   PubMedGoogle Scholar
• Mantovani A, Byrne CD, Benfari G, et al. Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week. J Am Coll Cardiol. 2022;79(2):180–191. doi:10.1016/j.jacc.2021.11.007.
   PubMed Web of Science ®Google Scholar
• Tsochatzis EA. Natural history of NAFLD: knowns and unknowns. Nat Rev Gastroenterol Hepatol. 2022;19(3):151–152. doi:10.1038/s41575-021-00565-8.
   PubMed Web of Science ®Google Scholar
• Hatasa M, Yoshida S, Takahashi H, et al. Relationship between NAFLD and periodontal disease from the view of clinical and basic research, and immunological response. Int J Mol Sci. 2021;22(7):22.
   Web of Science ®Google Scholar
• Ishikawa M, Yoshida K, Okamura H, et al. Oral Porphyromonas gingivalis translocates to the liver and regulates hepatic glycogen synthesis through the akt/GSK-3beta signaling pathway. Biochim Biophys Acta. 2013;1832(12):2035–2043. doi:10.1016/j.bbadis.2013.07.012.
   PubMed Web of Science ®Google Scholar
• Kuraji R, Ito H, Fujita M, et al. Porphyromonas gingivalis induced periodontitis exacerbates progression of non-alcoholic steatohepatitis in rats. Clin Exp Dent Res. 2016;2(3):216–225. doi:10.1002/cre2.41.
   PubMedGoogle Scholar
• Nakahara T, Hyogo H, Ono A, et al. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease. J Gastroenterol. 2018;53(2):269–280. doi:10.1007/s00535-017-1368-4.
   PubMed Web of Science ®Google Scholar
• Hasegawa Y, Nagano K. Porphyromonas gingivalis FimA and Mfa1 fimbriae: current insights on localization, function, biogenesis, and genotype. Jpn Dent Sci Rev. 2021;57:190–200. doi:10.1016/j.jdsr.2021.09.003.
   PubMed Web of Science ®Google Scholar
• Bostanci N, Belibasakis GN. Porphyromonas gingivalis: an invasive and evasive opportunistic oral pathogen. FEMS Microbiol Lett. 2012;333(1):1–9. doi:10.1111/j.1574-6968.2012.02579.x.
   PubMed Web of Science ®Google Scholar
• Yoshimura F, Murakami Y, Nishikawa K, et al. Surface components of Porphyromonas gingivalis. J Periodontal Res. 2009;44(1):1–12. doi:10.1111/j.1600-0765.2008.01135.x.
   PubMed Web of Science ®Google Scholar
• Lunar Silva I, Cascales E. Molecular strategies underlying Porphyromonas gingivalis virulence. J Mol Biol. 2021;433(7):166836. doi:10.1016/j.jmb.2021.166836.
   PubMed Web of Science ®Google Scholar
• Mei F, Xie M, Huang X, et al. Porphyromonas gingivalis and its systemic impact: current status. Pathogens. 2020;9(11):944. doi:10.3390/pathogens9110944.
   PubMed Web of Science ®Google Scholar
• Ahn J-S, Yang JW, Oh S-J, et al. Porphyromonas gingivalis exacerbates the progression of fatty liver disease via CD36-PPARγ pathway. BMB Rep. 2021;54(6):323–328. doi:10.5483/BMBRep.2021.54.6.050.
   PubMed Web of Science ®Google Scholar
• Alakhali MS, Al-Maweri SA, Al-Shamiri HM, et al. The potential association between periodontitis and non-alcoholic fatty liver disease: a systematic review. Clin Oral Investig. 2018;22(9):2965–2974. doi:10.1007/s00784-018-2726-1.
   PubMed Web of Science ®Google Scholar
• Ding LY, Liang LZ, Zhao YX, et al. Porphyromonas gingivalis-derived lipopolysaccharide causes excessive hepatic lipid accumulation via activating NF-kappaB and JNK signaling pathways. Oral Dis. 2019;25(7):1789–1797. doi:10.1111/odi.13153.
   PubMed Web of Science ®Google Scholar
• Ezhilarasan D. Deciphering the toxicological role of Porphyromonas gingivalis derived endotoxins in liver diseases. Environ Toxicol Pharmacol. 2021;88:103755. doi:10.1016/j.etap.2021.103755.
   PubMed Web of Science ®Google Scholar
• Nagasaki A, Sakamoto S, Arai T, et al. Elimination of Porphyromonas gingivalis inhibits liver fibrosis and inflammation in NASH. J Clin Periodontol. 2021;48(10):1367–1378. doi:10.1111/jcpe.13523.
   PubMed Web of Science ®Google Scholar
• Yamazaki K, Kato T, Tsuboi Y, et al. Oral Pathobiont-Induced changes in gut microbiota aggravate the pathology of nonalcoholic fatty liver disease in mice. Front Immunol. 2021;12:766170. doi:10.3389/fimmu.2021.766170.
   PubMed Web of Science ®Google Scholar
• Yoneda M, Naka S, Nakano K, et al. Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease. BMC Gastroenterol. 2012;12(1):16. doi:10.1186/1471-230X-12-16.
   PubMedGoogle Scholar
• Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537–2564. doi:10.1016/j.cell.2021.04.015.
   PubMed Web of Science ®Google Scholar
• Kang SH, Cho Y, Jeong SW, et al. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: big wave or ripple? Clin Mol Hepatol. 2021;27(2):257–269. doi:10.3350/cmh.2021.0067.
   PubMed Web of Science ®Google Scholar
• Gerges SH, Wahdan SA, Elsherbiny DA, et al. Non-alcoholic fatty liver disease: an overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Life Sci. 2021;271:119220. doi:10.1016/j.lfs.2021.119220.
   PubMed Web of Science ®Google Scholar
• Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov. 2016;15(4):249–274. doi:10.1038/nrd.2015.3.
   PubMed Web of Science ®Google Scholar
• Longo M, Meroni M, Paolini E, et al. Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending? Metabolism. 2021;117:154708. doi:10.1016/j.metabol.2021.154708.
   PubMed Web of Science ®Google Scholar
• Lebeaupin C, Vallee D, Hazari Y, et al. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J Hepatol. 2018;69(4):927–947. doi:10.1016/j.jhep.2018.06.008.
   PubMed Web of Science ®Google Scholar
• Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922. doi:10.1038/s41591-018-0104-9.
   PubMed Web of Science ®Google Scholar
• Tilg H, Adolph TE, Moschen AR. Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: revisited after a decade. Hepatology. 2021;73(2):833–842. doi:10.1002/hep.31518.
   PubMed Web of Science ®Google Scholar
• Furusho H, Miyauchi M, Hyogo H, et al. Dental infection of Porphyromonas gingivalis exacerbates high fat diet-induced steatohepatitis in mice. J Gastroenterol. 2013;48(11):1259–1270. doi:10.1007/s00535-012-0738-1.
   PubMed Web of Science ®Google Scholar
• Tian J, Liu C, Zheng X, et al. Porphyromonas gingivalis induces insulin resistance by increasing BCAA levels in mice. J Dent Res. 2020;99(7):839–846. doi:10.1177/0022034520911037.
   PubMed Web of Science ®Google Scholar
• Aleksijevic LH, Aleksijevic M, Skrlec I, et al. Porphyromonas gingivalis virulence factors and clinical significance in periodontal disease and coronary artery diseases. Pathogens. 2022;11(10):1173. doi:10.3390/pathogens11101173.
   PubMed Web of Science ®Google Scholar
• Tribble GD, Kerr JE, Wang BY. Genetic diversity in the oral pathogen Porphyromonas gingivalis: molecular mechanisms and biological consequences. Future Microbiol. 2013;8(5):607–620. doi:10.2217/fmb.13.30.
   PubMed Web of Science ®Google Scholar
• Atanasova KR, Yilmaz O. Looking in the Porphyromonas gingivalis cabinet of curiosities: the microbium, the host and cancer association. Mol Oral Microbiol. 2014;29(2):55–66. doi:10.1111/omi.12047.
   PubMed Web of Science ®Google Scholar
• Ahmadi P, Mahmoudi M, Kheder RK, et al. Impacts of Porphyromonas gingivalis periodontitis on rheumatoid arthritis autoimmunity. Int Immunopharmacol. 2023;118:109936. doi:10.1016/j.intimp.2023.109936.
   PubMed Web of Science ®Google Scholar
• Li Y, Guo R, Oduro PK, et al. The relationship between Porphyromonas gingivalis and rheumatoid arthritis: a meta-analysis. Front Cell Infect Microbiol. 2022;12:956417. doi:10.3389/fcimb.2022.956417.
   PubMed Web of Science ®Google Scholar
• Zhou N, Zou F, Cheng X, et al. Porphyromonas gingivalis induces periodontitis, causes immune imbalance, and promotes rheumatoid arthritis. J Leukoc Biol. 2021;110(3):461–473. doi:10.1002/JLB.3MA0121-045R.
   PubMed Web of Science ®Google Scholar
• Bartold PM, Marino V, Cantley M, et al. Effect of Porphyromonas gingivalis-induced inflammation on the development of rheumatoid arthritis. J Clin Periodontol. 2010;37(5):405–411. doi:10.1111/j.1600-051X.2010.01552.x.
   PubMed Web of Science ®Google Scholar
• Mikuls TR, Payne JB, Yu F, et al. Periodontitis and Porphyromonas gingivalis in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(5):1090–1100. doi:10.1002/art.38348.
   PubMed Web of Science ®Google Scholar
• Yamakawa M, Ouhara K, Kajiya M, et al. Porphyromonas gingivalis infection exacerbates the onset of rheumatoid arthritis in SKG mice. Clin Exp Immunol. 2016;186(2):177–189. doi:10.1111/cei.12847.
   PubMed Web of Science ®Google Scholar
• Nakano K, Wada K, Nomura R, et al. Characterization of aortic aneurysms in cardiovascular disease patients harboring Porphyromonas gingivalis. Oral Dis. 2011;17(4):370–378. doi:10.1111/j.1601-0825.2010.01759.x.
   PubMed Web of Science ®Google Scholar
• Deshpande RG, Khan M, Genco CA. Invasion strategies of the oral pathogen porphyromonas gingivalis: implications for cardiovascular disease. Invasion Metastasis. 1998;18(2):57–69. doi:10.1159/000024499.
   PubMedGoogle Scholar
• Ruan Q, Guan P, Qi W, et al. Porphyromonas gingivalis regulates atherosclerosis through an immune pathway. Front Immunol. 2023;14:1103592. doi:10.3389/fimmu.2023.1103592.
   PubMed Web of Science ®Google Scholar
• Zhang J, Xie M, Huang X, et al. The effects of Porphyromonas gingivalis on atherosclerosis-related cells. Front Immunol. 2021;12:766560. doi:10.3389/fimmu.2021.766560.
   PubMed Web of Science ®Google Scholar
• Li L, Messas E, Batista EL, Jr., et al. Porphyromonas gingivalis infection accelerates the progression of atherosclerosis in a heterozygous apolipoprotein E-deficient murine model. Circulation. 2002;105(7):861–867. doi:10.1161/hc0702.104178.
   PubMed Web of Science ®Google Scholar
• Hayashi C, Viereck J, Hua N, et al. Porphyromonas gingivalis accelerates inflammatory atherosclerosis in the innominate artery of ApoE deficient mice. Atherosclerosis. 2011;215(1):52–59. doi:10.1016/j.atherosclerosis.2010.12.009.
   PubMed Web of Science ®Google Scholar
• Blasco-Baque V, Garidou L, Pomie C, et al. Periodontitis induced by Porphyromonas gingivalis drives periodontal microbiota dysbiosis and insulin resistance via an impaired adaptive immune response. Gut. 2017;66(5):872–885. doi:10.1136/gutjnl-2015-309897.
   PubMed Web of Science ®Google Scholar
• Singhrao SK, Harding A, Poole S, et al. Porphyromonas gingivalis periodontal infection and its putative links with alzheimer’s disease. Mediators Inflamm. 2015;2015:137357–137310. doi:10.1155/2015/137357.
   PubMed Web of Science ®Google Scholar
• Liu S, Butler CA, Ayton S, et al. Porphyromonas gingivalis and the pathogenesis of alzheimer’s disease. Crit Rev Microbiol. 2023. doi:10.1080/1040841X.2022.2163613.
   Web of Science ®Google Scholar
• Elwishahy A, Antia K, Bhusari S, et al. Porphyromonas Gingivalis as a risk factor to alzheimer’s disease: a systematic review. J Alzheimers Dis Rep. 2021;5(1):721–732. doi:10.3233/ADR-200237.
   PubMedGoogle Scholar
• Olsen I. Porphyromonas gingivalis-Induced neuroinflammation in alzheimer’s disease. Front Neurosci. 2021;15:691016. doi:10.3389/fnins.2021.691016.
   PubMed Web of Science ®Google Scholar
• Olsen I. Possible effects of Porphyromonas gingivalis on the blood-brain barrier in alzheimer’s disease. Expert Rev anti Infect Ther. 2021;19(11):1367–1371. doi:10.1080/14787210.2021.1925540.
   PubMed Web of Science ®Google Scholar
• Olsen I, Yilmaz O. Possible role of Porphyromonas gingivalis in orodigestive cancers. J Oral Microbiol. 2019;11(1):1563410. doi:10.1080/20002297.2018.1563410.
   PubMed Web of Science ®Google Scholar
• Dominy SS, Lynch C, Ermini F, et al. Porphyromonas gingivalis in alzheimer’s disease brains: evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv. 2019;5(1):eaau3333. doi:10.1126/sciadv.aau3333.
   PubMed Web of Science ®Google Scholar
• Gao S, Li S, Ma Z, et al. Presence of Porphyromonas gingivalis in esophagus and its association with the clinicopathological characteristics and survival in patients with esophageal cancer. Infect Agent Cancer. 2016;11:3.
   PubMed Web of Science ®Google Scholar
• Gnanasekaran J, Binder Gallimidi A, Saba E, et al. Intracellular Porphyromonas gingivalis promotes the tumorigenic behavior of pancreatic carcinoma cells. Cancers (Basel). 2020;12(8):2331. doi:10.3390/cancers12082331.
   PubMedGoogle Scholar
• Da Venezia C, Hussein N, Hernandez M, et al. Assessment of cardiovascular risk in women with periodontal diseases according to C-reactive protein levels. Biomolecules. 2021;11(8):1238. doi:10.3390/biom11081238.
   PubMed Web of Science ®Google Scholar
• Stanisic D, Jeremic N, Singh M, et al. Porphyromonas gingivalis induces cardiovascular dysfunction. Can J Physiol Pharmacol. 2023;101(8):413–424. doi:10.1139/cjpp-2022-0392.
   PubMedGoogle Scholar
• Olsen I, Taubman MA, Singhrao SK. Porphyromonas gingivalis suppresses adaptive immunity in periodontitis, atherosclerosis, and alzheimer’s disease. J Oral Microbiol. 2016;8(1):33029. doi:10.3402/jom.v8.33029.
   PubMed Web of Science ®Google Scholar
• Tang Z, Liang D, Cheng M, et al. Effects of Porphyromonas gingivalis and its underlying mechanisms on Alzheimer-like tau hyperphosphorylation in Sprague-Dawley rats. J Mol Neurosci. 2021;71(1):89–100. doi:10.1007/s12031-020-01629-1.
   PubMedGoogle Scholar
• Xie M, Tang Q, Nie J, et al. BMAL1-Downregulation aggravates Porphyromonas gingivalis-induced atherosclerosis by encouraging oxidative stress. Circ Res. 2020;126(6):e15–e29. doi:10.1161/CIRCRESAHA.119.315502.
   PubMed Web of Science ®Google Scholar
• Wan M, Liu J, Ouyang X. Nucleotide-binding oligomerization domain 1 regulates Porphyromonas gingivalis-induced vascular cell adhesion molecule 1 and intercellular adhesion molecule 1 expression in endothelial cells through NF-kappaB pathway. J Periodontal Res. 2015;50(2):189–196. doi:10.1111/jre.12192.
   PubMed Web of Science ®Google Scholar
• Bhandari S, Gupta E, Abdul MKM, et al. Association ofPorphyromonas gingivalisSerum antibody levels and non-alcoholic fatty liver disease (NAFLD): an NHANES study: 1004. Off J Am Coll Gastroenterol| ACG. 2017;112:S559. doi:10.14309/00000434-201710001-01005.
   Web of Science ®Google Scholar
• Chen W, Alshaikh A, Kim S, et al. Porphyromonas gingivalis impairs oral epithelial barrier through targeting GRHL2. J Dent Res. 2019;98(10):1150–1158. doi:10.1177/0022034519865184.
   PubMed Web of Science ®Google Scholar
• Bregaint S, Boyer E, Fong SB, et al. Porphyromonas gingivalis outside the oral cavity. Odontology. 2022;110(1):1–19. doi:10.1007/s10266-021-00647-8.
   PubMed Web of Science ®Google Scholar
• Abe N, Baba A, Takii R, et al. Roles of arg- and lys-gingipains in coaggregation of Porphyromonas gingivalis: identification of its responsible molecules in translation products of rgpA, kgp, and hagA genes. Biol Chem. 2004;385(11):1041–1047. doi:10.1515/BC.2004.135.
   PubMed Web of Science ®Google Scholar
• Sasaki N, Katagiri S, Komazaki R, et al. Endotoxemia by Porphyromonas gingivalis injection aggravates non-alcoholic fatty liver disease, disrupts glucose/lipid metabolism, and alters gut microbiota in mice. Front Microbiol. 2018;9:2470. doi:10.3389/fmicb.2018.02470.
   PubMed Web of Science ®Google Scholar
• Sumida Y, Niki E, Naito Y, et al. Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic Res. 2013;47(11):869–880. doi:10.3109/10715762.2013.837577.
   PubMed Web of Science ®Google Scholar
• Narasimhan S, Gokulakrishnan K, Sampathkumar R, et al. Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. Clin Biochem. 2010;43(10-11):815–821. doi:10.1016/j.clinbiochem.2010.04.003.
   PubMed Web of Science ®Google Scholar
• Kumar J, Teoh SL, Das S, et al. Oxidative stress in oral diseases: understanding its relation with other systemic diseases. Front Physiol. 2017;8:693. doi:10.3389/fphys.2017.00693.
   PubMed Web of Science ®Google Scholar
• Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3(1):23–35. doi:10.1038/nri978.
   PubMed Web of Science ®Google Scholar
• Murray PJ. Macrophage polarization. Annu Rev Physiol. 2017;79(1):541–566. doi:10.1146/annurev-physiol-022516-034339.
   PubMed Web of Science ®Google Scholar
• Kazankov K, Jorgensen SMD, Thomsen KL, et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol. 2019;16(3):145–159. doi:10.1038/s41575-018-0082-x.
   PubMed Web of Science ®Google Scholar
• Yu S, Ding L, Liang D, et al. Porphyromonas gingivalis inhibits M2 activation of macrophages by suppressing alpha-ketoglutarate production in mice. Mol Oral Microbiol. 2018;33(5):388–395. doi:10.1111/omi.12241.
   PubMed Web of Science ®Google Scholar
• Wan J, Benkdane M, Teixeira-Clerc F, et al. M2 kupffer cells promote M1 kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology. 2014;59(1):130–142. doi:10.1002/hep.26607.
   PubMed Web of Science ®Google Scholar
• Saha S, Panigrahi DP, Patil S, et al. Autophagy in health and disease: a comprehensive review. Biomed Pharmacother. 2018;104:485–495. doi:10.1016/j.biopha.2018.05.007.
   PubMed Web of Science ®Google Scholar
• Kitada M, Koya D. Autophagy in metabolic disease and ageing. Nat Rev Endocrinol. 2021;17(11):647–661. doi:10.1038/s41574-021-00551-9.
   PubMed Web of Science ®Google Scholar
• Mizushima N, Levine B. Autophagy in human diseases. N Engl J Med. 2020;383(16):1564–1576. doi:10.1056/NEJMra2022774.
   PubMed Web of Science ®Google Scholar
• Hazari Y, Bravo-San Pedro JM, Hetz C, et al. Autophagy in hepatic adaptation to stress. J Hepatol. 2020;72(1):183–196. doi:10.1016/j.jhep.2019.08.026.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Rodriguez A, Mayoral R, Agra N, et al. Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD. Cell Death Dis. 2014;5(4):e1179–e1179. doi:10.1038/cddis.2014.162.
   PubMedGoogle Scholar
• Czaja MJ. Function of autophagy in nonalcoholic fatty liver disease. Dig Dis Sci. 2016;61(5):1304–1313. doi:10.1007/s10620-015-4025-x.
   PubMed Web of Science ®Google Scholar
• Zaitsu Y, Iwatake M, Sato K, et al. Lipid droplets affect elimination of Porphyromonas gingivalis in HepG2 cells by altering the autophagy-lysosome system. Microbes Infect. 2016;18(9):565–571. doi:10.1016/j.micinf.2016.05.004.
   PubMed Web of Science ®Google Scholar
• Rodrigues PH, Belanger M, Dunn W, Jr., et al. Porphyromonas gingivalis and the autophagic pathway: an innate immune interaction? Front Biosci. 2008;13(13):178–187. doi:10.2741/2668.
   PubMedGoogle Scholar
• Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7(12):691–701. doi:10.1038/nrgastro.2010.172.
   PubMed Web of Science ®Google Scholar
• Compare D, Coccoli P, Rocco A, et al. Gut–liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2012;22(6):471–476. doi:10.1016/j.numecd.2012.02.007.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Arimatsu K, Kato T, et al. Oral administration of P. gingivalis induces dysbiosis of gut microbiota and impaired barrier function leading to dissemination of enterobacteria to the liver. PLoS One. 2015;10(7):e0134234. doi:10.1371/journal.pone.0134234.
   PubMed Web of Science ®Google Scholar
• Lang S, Schnabl B. Microbiota and fatty liver disease—the known, the unknown, and the future. Cell Host Microbe. 2020;28(2):233–244. doi:10.1016/j.chom.2020.07.007.
   PubMed Web of Science ®Google Scholar
• Aron-Wisnewsky J, Vigliotti C, Witjes J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol. 2020;17(5):279–297. doi:10.1038/s41575-020-0269-9.
   PubMed Web of Science ®Google Scholar
• Simas AM, Kramer CD, Genco CA. Diet-Induced non-alcoholic fatty liver disease and associated gut dysbiosis are exacerbated by oral infection. Front Oral Health. 2021;2:784448. doi:10.3389/froh.2021.784448.
   PubMedGoogle Scholar
• Arimatsu K, Yamada H, Miyazawa H, et al. Oral pathobiont induces systemic inflammation and metabolic changes associated with alteration of gut microbiota. Sci Rep. 2014;4(1):4828. doi:10.1038/srep04828.
   PubMedGoogle Scholar
• Komazaki R, Katagiri S, Takahashi H, et al. Periodontal pathogenic bacteria, Aggregatibacter actinomycetemcomitans affect non-alcoholic fatty liver disease by altering gut microbiota and glucose metabolism. Sci Rep. 2017;7(1):13950. doi:10.1038/s41598-017-14260-9.
   PubMed Web of Science ®Google Scholar